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Abstract.  Polyclonal antibodies against plasminogen 
activator inhibitor type-I (PAl-l) caused rapid retrac- 
tion and rounding of substrate-attached HT-1080 cells. 
The kinetics and extent of antibody-mediated cell 
rounding were not dependent on either urokinase or 
plasmin activity. Cells adherent to vitronectin-coated 
substrates detached within 2 h of antibody addition. 
Cells adherent to fibronectin were unaffected by the 
antibodies.  Immunoblotting of substrate-attached mate- 
rial indicated that HT-1080 cells deposited PAId  into 
vitronectin,  but not fibronectin, dependent contacts. 
These data suggest that the antibody-mediated cell 
rounding  resulted from a  steric disruption of 
vitronectin-dependent adhesions,  indicating that the 
binding site on vitronectin for PAI-I  is near,  but does 
not overlap, the binding site for vitronectin receptor. 
The accumulation of PAId  into vitronectin-dependent 
adhesion sites correlated temporally with the preferen- 
tial degradation of fibronectin from the substrate.  HT- 
1080 cells adherent to either fibronectin or vitronectin 
were able to activate exogenous plasminogen to plas- 
min.  Plasmin levels were increased 200%  on cells ad- 
herent to fibronectin and  100%  on cells adherent to 
vitronectin.  In the presence of a neutralizing  antibody 
against PAl-l, vitronectin adherent cells activated plas- 
minogen to the same extent as fibronectin adherent 
cells. Plasmin levels of 200%  above baseline were as- 
sociated with retraction of cells from the substrate. 
The ability of vitronectin adherent cells to activate ex- 
ogenous plasmin was completely blocked in the pres- 
ence of neutralizing  antibodies against urokinase. 
These data represent the first demonstration that 
vitronectin-associated PAI-1 regulates urokinase in fo- 
cal contact areas. 
N 
'UMEROUS studies  over the past several  years have 
suggested a relationship  between neoplastic growth 
and the fibrinolytic system (reviewed in Dano et al., 
1985; Markus,  1988). In vitro, cell transformation  is often 
associated with increased production of plasminogen  activa- 
tors, which convert the proenzyme plasminogen  to plasmin. 
HT-1080 is a highly proteolytic cell line derived from a hu- 
man fibrosarcoma (Rasheed et al.,  1974). The rapid degra- 
clarion of extracellular  matrix by these cells can be partially 
blocked by inhibitors of uroldnase-type plasminogen  activa- 
tors, suggesting a role for plasmin in the destruction of ma- 
trix (Bergman  et al.,  1986;  Reich  et al.,  1988).  HT-1080 
cells secrete uroldnase which has been localized to vinculin- 
rich areas of cell-substratum adhesion, suggesting that the 
enzyme is concentrated in focal contacts (Pollanen  et al., 
1987, 1988; Herbert and Baker, 1988). In culture,  a number 
of cell types have been shown to form focal contacts on the 
adhesive glycoproteins, fibronectin,  and vitronectin,  present 
in serum (Singer  et al.,  1988).  It is clear that in order for 
a proteolyticaUy active cell to maintain adhesion, the uro- 
kinase and/or plasmin in contact areas must be tightly regu- 
lated. 
Hasminogen  activator  inhibitor  type-I  (PAl-l)'  is  the 
most important specific inhibitor  of plasminogen  activators. 
In vivo, PAId has been isolated  from serum, platelets,  and 
placenta (Kruithof,  1988). In vitro,  PAl-1 is secreted by en- 
dothelial  cells (Loskutoff and Edgington,  1977), fibroblasts 
(Laiho et al.,  1986),  and HT-1080 cells (Andreasen  et al., 
1986).  PAl-1 secreted by endothelial  cells retains activity 
through  association with the extraceUular  matrix (Mimuro 
et al., 1987) but becomes inactive in solution (Levin, 1986). 
Unlike  endothelial  ceils,  HT-1080 cells do not  assemble 
significant  amounts  of extracellular  matrix  (Oliver et al., 
1983; McKeown-Longo and Etzler,  1987); however, they do 
deposit PAI-1 onto the substratum (Pollanen  et al.,  1987). 
Treating  HT-1080  cells  with  dexamethasone,  which  in- 
creases  PAI-1 levels  in  the  substratum  (Pollanen  et  al., 
1987),  also alters  cell morphology.  The cells appear well 
spread and more adherent  to the substratum (Oliver et al., 
1983;  McKeown-Longo  and  Etzler,  1987).  The  studies 
presented here were undertaken to investigate  the role of 
1. Abbreviations  used in this paper: PAId, plasminogen activator inhibitor 
type-I; SAM, substrate-attached material. 
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dicate  that  immediately after  plating,  the  cells  degrade 
fibronectin and deposit PAI-1 onto vitronectin. This PAI-1 
protects vitronectin from plasmin degradation and the cells 
remain adherent to vitronectin-PAI-1 complexes. 
Materials and Methods 
Cell Cultures 
Human fibrosarcoma cells, HT-1080, were a gift from Dr. Noellyn Oliver 
(Tufts University), and stock cultures were grown in plastic tissue culture 
dishes (55  cm2;  Coming Glass Works,  Coming,  NY)  in MEM  (Gibco 
Laboratories, Grand Island, NY) supplemented with 10% FBS (HyClone 
Laboratories, Inc., Logan, UT), 100 IU/ml penicillin, and 100/~g/ml strep- 
tomycin (pen/strep; Flow Laboratories, Inc., McLean, VA). Experiments 
were performed in either 12-well  Linbro tissue culture plates (4.5 cm2; 
Flow Laboratories, Inc.) or 24-well tissue culture plates (1.9 era2; Coming 
Glass Works). 
For those experiments requiring the absence of plasminogen, FBS (100 
ml) was depleted of plasminogen by three passes over a Lysine-Sepharose 
4B (Sigma Chemical Co., St. Louis, MO) column equilibrated with 0.3 M 
potassium phosphate (pH Z4) containing 1 mM EDTA (Deutsch and Mertz, 
1970).  HT-1080 cells were plated in MEM with 10% FBS depleted of plas- 
minogen and grown to confluence. To remove cell-bound plasmin, cells 
were washed in PBS containing 1 mM tranexamic acid. Human plasmino- 
gen  was  purified  from  serum  by  affinity  chromatography  on  iysine- 
Sepharose as described above. Plasminogen was eluted from the column 
with 0.1 M potassium phosphate (pH 7.4) containing 0.2 M E-amino caproic 
acid. Plasminogen was dialyzed against PBS and sterile filtered before use. 
Plasminogen did not contain any active plasmin when tested in the Spectro- 
zyme PL assay. 
Purified human fibronectin and human vitronectin were the generous gift 
of Dr.  Dearie E  Mosher (Departments of Medicine and  Physiological 
Chemistry,  University  of Wisconsin  Medical  School,  Madison,  WI). 
Purified proteins were used to coat 24-well tissue culture plates. Proteins 
were diluted in PBS and incubated in wells for 1 h. The wells were then 
washed three times with PBS. Wells received a second coat of PBS contain- 
ing 1% BSA and were then washed three times with PBS. HT-1080 cells to 
be plated onto these wells were trypsinized from stock culture plates, 
washed, and resuspended at 5  x  10  ~ cells/ml in MEM supplemented with 
1% BSA.  1 ml of the cell suspension was plated into each well. 
Substratum-attached material (SAM) was isolated by a modification of 
the method of Rosen and Culp (1977).  Briefly, cell layers were rinsed three 
times with 4°C MEM and incubated in 10 mM Hepes, 1 mM EGTA (pH 
7.4) at 37°C for 30 min. The cells were removed with gentle agitation and 
the wells were washed three times with PBS. The SAM left on the bottom 
of each well was solubilized with reducing gel sample buffer. 
The following reagents were used in inhibition studies: Aprotinin (#517; 
American  Diagnostica,  New  York,  NY);  Diisopropyl-fluorophosphate 
(DFP),  p-nitrophenyl-guanidino-benzoate (NPGB),  and  PMSF  (Sigma 
Chemical Co.). The following inhibitory mAbs were also used: an anticata- 
lytic antibody to human urokinase (anti-uPA, #394; American Diagnostica) 
and to human tissue plasminogen activator (anti-tPA, #374B; American Di- 
agnostica); and an antibody to the active site of PAI-1 (#379; American Di- 
agnostica). Specific amounts are provided in the figure legends. 
Purification of  PAI-1 and Isolation of  Antibodies 
HT-1080  cells were seeded into plastic roller bottles (850 cm2;  Coming 
Glass Works) and allowed to grow to confluency. The medium was removed 
and the incubation continued for 24 h in medium containing 10  -7 M dexa- 
methasone (Sigma Chemical Co.). At this time, the medium was removed 
and MEM containing 10  -7 M  dexamethasone without serum was added 
and the cells incubated for another 24 h. This conditioned medium was col- 
lected and PMSF was added to a final concentration of 1 mM. Conditioned 
medium was filtered through a 0.22-/~m nylon filter (Coming Glass Works) 
and concentrated •40-fold  by ultrafiltration on a YM30 membrane (mol/wt 
cut-off 30,000;  Amicon Corp., Danvers, MA). The concentrate was dia- 
lyzed against 10 mM sodium phosphate (pH 7.4) and PAI-1 was isolated 
by chromatography on heparin-Sepharose CL-tB  (Pharmacia,  Uppsala, 
Sweden). Bound proteins were ehited with 1 M NaC1, dialyzed against PBS, 
and passed over gelatin-Sepharose 4B (Pharmacia) to remove fibronectin. 
The pass through was collected, lyophilized, resuspended in reducing gel 
sample buffer, and further purified by preparative SDS gel electrophoresis. 
When analyzed by Western immunoblotting, purified PAI-1 contained no 
urokinase. Since this assay can detect 100 ng of urokinase, the PAI-1 prepa- 
ration contained <1% contamination with urokinase (data not shown). This 
preparation of PAI-1 was used as an immunogen in rabbits for the production 
of antibodies. Specificity and titer of antiserum was determined by Western 
immunoblotting and ELISA. 
Immunoglobulins (IgGs)  were isolated from antiserum using protein 
A-Sepharose. Immune or nonimmune rabbit serum was passed over a pro- 
tein A-Sepharose CL-4B (Pharmacia) column equilibrated with 100 mM 
sodium phosphate (pH 7.0).  Bound IgG was ehited with 1 M acetic acid, 
100 mM glycine (pH 3.0),  and the eluate was immediately neutralized to 
pH 7.4 with 1 M Tris (pH 10.0). The eluate from the immune serum was 
designated anti-PAI-1 IgG and that from the nonimmune serum was desig- 
nated normal IgG. Both eluates were then dialyzed against PBS and the con- 
centration determined by the OD at 280 nm using the absorbance at 280 
mn of a 1% solution of rabbit IgG (i.e., 13.5). The samples were filter steri- 
lized and stored at  -80°C for future use. 
For the preparation of Fab fragments, anti-PAI-1 or normal IgG was dia- 
lyzed against 20 mM sodium phosphate, 10 mM EDTA (pH 7.0), and con- 
centrated to ,,o20 mg/ml in dialysis tubing using dry polyethylene glycol 
(tool wt 15,000;  Aldrich Chemical Co., Milwaukee, WI). IgG (10 mg/ml) 
was digested with 1.75 U of immobilized papain (cross-linked 6% beaded 
agarose, 7 U/ml; Pierce Chemical Co., Rockford, IL) in the presence of cys- 
teine. The digestion solution was incubated overnight on a shaker platform 
at high speed at 37°C. The resulting solution was clarified by centrifugation. 
The supernatant was applied to a protein A-Sepharose column under the 
same conditions as described above. The pass through (containing the Fab 
fragments) was collected and dialyzed against PBS and the concentration 
determined by the OD at 280 mn using the absorbance at 280 nm of a  1% 
solution of rabbit FOb fragments, i.e., 15.0). The samples were filter steri- 
lized and stored at  -80°C for future use. 
Iodination of  Proteins 
Fibronectin was iodinated as previously described (McKeown-Longo and 
Mosher, 1983).  Vitronectin was iodinated in a similar fashion except the 
chloramine-T reaction was stopped with an equimolar concentration of so- 
dium metabisulfite (Fisher Scientific, Fair Lawn, N J). Free iodine was re- 
moved ",y chromatography on G-25 (Sigma Chemical Co.) in PBS. Iodi- 
nated proteins were stabilized with  1%  BSA, 0.1  mM PMSE  and then 
dialyzed against PBS. Samples were frozen at  -80"C for future use. In- 
tegrity of  the labeled protein was assessed by gel electrophoresis  and autora- 
diography. Specific activity of each protein was adjusted to 1 mCi/mg be- 
fore use. 
Plasmin Assay 
Plasmin activity was assayed using the chromogenic substrate, Spectrozyme 
PL (#251;  American Diagnostica).  To  measure cell-associated plasmin, 
cells in 24-well plates were washed three times with phenol red-free MEM. 
Spectrozyme PL, 0.25 mM in MEM (250/zl), was added to each well and 
incubated for 90 min at 37°C. Samples (150 t~I) were removed from each 
well and added to 50/zl 50% acetic acid in 96-well ELISA plates (Coming 
Glass Works). The OD was measured at 410 nm using a Dynatech MR600 
multiplate reader. Wells that did not contain cells were used as controls. To 
measure total plasmin activity, the conditioned medium was not removed 
from the well before the assay. 
Results 
Purification of  PAl-1 
Previous studies have shown that dexamethasone induces a 
10-fold increase in the synthesis and secretion of PAI4  by 
HT-1080 cells  (Andreasen et al.,  1987).  This  increase  in 
PAI-1 synthesis is accompanied by accumulation of a fibro- 
nectin containing extracellular matrix and by changes in cell 
morphology (Oliver et al., 1983; McKeown-Longo  and Etz- 
ler, 1987).  The cells appear more well spread and better at- 
tached to the substrate.  It is not clear from these earlier 
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(lane  A)  TCA  precipitation 
of  serum-free  conditioned 
medium  from  HT-1080 cell 
monolayers treated with dexa- 
methasone. (lane B) Heparin- 
Sepharose bound  fraction  of 
pooled  conditioned  medium. 
(lane  C)  Gelatin-Sepharose 
pass through of heparin-bound 
fraction. (lane D) Protein pu- 
rified  by  preparative  SDS- 
PAGE (arrowhead). Tiffs pro- 
tein  reacted  with  mAbs  to 
PAI-1 in an immunoblot (data 
not  shown). Position of mo- 
lecular  weight  markers  is 
shown on the left. 
studies whether the morphological changes preceed or fol- 
low the accumulation of matrix. The purpose of the current 
study was to probe the role of PAid  in the maintenance of 
HT-1080 cell adhesion. 
Human PAId was purified from the conditioned medium 
of dexamethasone-treated  HT-1080 cells.  Fig.  1,  lane A, 
shows that PAid (designated by the arrowhead)  can be de- 
tected in the conditioned medium of  dexamethasone-induced 
HT-1080 cells. When the conditioned medium is passed over 
a  heparin affinity column, the preparation is enriched for 
both PAId  and fibronectin (Fig.  1, lane B). Fibronectin is 
removed from the preparation by gelatin affinity chromatog- 
raphy (Fig.  1, lane C) and the PAId is further purified by 
preparative SDS-PAGE (Fig.  1,  lane D).  This preparation 
was used as immunogen to produce polyclonal anti-PAid- 
antibodies in rabbits. 
Anti-PAid IgG was purified as described in Materials and 
Methods and the specificity of  the antibodies was determined 
by Western immunoblots (Fig. 2). When tested against the 
proteins recovered from HT-1080 conditioned medium, the 
antibodies reacted with both a 48,000 and a 44,000 mol wt 
protein (Fig. 2, lanes A and a). These two proteins were also 
recognized using  an mAb  against  human  PAId  (data not 
shown), indicating that they represent intact PAId and the 
inactive PAId cleavage product (Nielsen et al., 1986). No re- 
activity of the antibodies could be detected against fibronec- 
tin, vitronectin, urokinase, or any other proteins present in 
the conditioned medium (Fig.  2). 
Anti-PAl-1 Antibodies Cause HT-1080 Cells to Detach 
from the Substratum 
To probe the role of PAid in maintaining HT-1080 cell adhe- 
sion, polyclonal antibodies to PAId were added to HT-1080 
cell monolayers. HT-1080 cells grew as substrate-attached 
cells when cultured on tissue culture plastic; however, like 
most transformed cells, they did not exhibit contact inhibi- 
tion. Once the cells covered the bottom of the dish, they con- 
tinued to grow in clusters on the surface of the monolayer 
(Fig. 3 A). IgGs prepared from both normal rabbit serum and 
anti-PAid antiserum were incubated with confluent cultures 
of HT-1080 cells and compared for their effects on cell mor- 
phology. Addition of anti-PAid IgG resulted in disruption of 
cell-substratum adhesion. Cells retracted from one another 
and partially detached from the substratum,  resulting in a 
rounded appearance and exposure of  underlying plastic (Fig. 
3  B).  Antibody concentrations as low as  12.5 #g/ml dis- 
rupted cell adhesion as effectively as  100/zg/ml (data not 
shown).  This response could be reproduced with the Fab 
portion of the antibody (Fig. 3 D). Time course experiments 
showed that cell retraction was evident 3 h after the addition 
of anti-PAid IgG (data not shown). By 5 h all cells were com- 
pletely rounded but still  attached to the substrate (Fig.  3). 
With  longer  incubation times  (18-24  h),  cells eventually 
detached from the substrate and floated in clusters in the 
medium (data not shown). This effect was specific for anti- 
PAId IgG as polyclonal antibodies against urokinase did not 
disrupt adhesion (data not shown).  The antibody was not 
toxic to the cells since detached cells excluded vital dyes and 
replated normally after removal of the antibody (data not 
shown). An mAb against the active site of PAId was also not 
effective in  mediating  cell detachment  in  similar  studies, 
however,  the  addition  of  a  secondary  antibody  directed 
against the monoclonal did result in disruption of adhesion 
(data  not  shown).  These  data  suggest  that  the  antibody- 
Figure 2. Immunoblot analysis of anti-PAI-1 antibody specificity. 
(lanes A-D) Amido Black stain of nitrocellulose containing elec- 
troblotted proteins. (lanes a-d) The nitrocellulose was incubated 
with  the  anti-PAid  antibodies  (25 /~g/ml) and developed using 
4-chloro-l-naphthol  and HRP-conjugated  goat anti-rabbit IgG. (lanes 
A and a) TCA precipitation of HT-1080 cell-conditioned medium. 
(lanes B and b) Purified human vitronectin (10/zg).  (lanes C and 
c) Purified human fibronectin (10 ~g).  (lanes D and d) Purified 
active human urokinase (10/~g). Intact PAId is indicated by the 
arrowhead.  Position of molecular  weight markers  is  shown on 
the left. 
Ciambrone and McKeown-Longo  Adherence to Vitronectin-PAl-1 Complexes  2185 Figure 3. Effect of anti-PAid  on HT-1080 cells. Confluent cultures of ceils were incubated with normal or anti-PAl-1 IgG or Fab fragments 
for 5 h. Antibodies were added to cells in either complete medium (A and B) or MEM (C and D). (A) Normal IgG 100/~g/ml; (B) anti-PAL1 
100/~g/ml;  (C) normal Fab 50 t~g/ml; (D) anti-PAl-1 Fab 50/~g/ml.  Bar, 25/~m. 
mediated rounding  was not due to  inhibition  of PAl-1  ac- 
tivity. 
Additional  experiments  were  done  to  address  whether 
anti-PAl-1  IgG could be interferring  with PAid-dependent 
inhibition  of cell-associated urokinase.  Experiments  were 
done to address directly the possible role of urokinase and 
plasmin  in  the  cell  rounding  phenomenon.  To  eliminate 
urokinase-dependent plasminogen activation, an mAb against 
the active site of urokinase was used. Potential residual plas- 
min activity was inhibited  with aprotinin.  In combination, 
these modulators had no effect on the kinetics or degree of 
anti-PAl-l-mediated cell rounding  (Fig. 4  C).  In other ex- 
periments,  cells were washed with tranexamic acid to re- 
move bound plasmin (Stephens et al., 1989) and cultured for 
one passage in plasminogen-depleted serum. The serine pro- 
tease inhibitor p-nitrophenyl-guanidino-benzoate (100 f+M) 
was added in combination with aprotinin (200 KIU/ml) to 
these cultures. No effect on the anti-PAl-l-mediated round- 
ing was observed (data not shown). The addition of the ser- 
ine protease inhibitors, PMSF (1 mM), or diisopropylfluoro- 
phosphate (250 #M) also had no effect on antibody-mediated 
cell rounding (data not shown). Results shown in Figs. 3 and 
4  suggest that the rounding of the cells in response to anti- 
PAl-1 is not due to enhanced proteolysis but results from a 
steric disruption of the interaction of the cells with the sub- 
strate. 
Anti-PAl-1 Disrupts HT-1080 Cell Adhesion to 
Vitronectin and Not to Fibronectin 
HT-1080 cells do not assemble detectable amounts  of ex- 
tracellular matrix (Oliver et al., 1983; McKeown-Longo and 
The Jourfial of Cell Biology, Volume 111, 1990  2186 Figure 4. Effect of plasmin inhibition on anti-PAI-l-mediated detachment.  Monolayers of HT-1080 cells were grown to confluence in com- 
plete medium.  The cells shown in C received  100/~g/ml  of anticatalytic  antiurokinase antibody and aprotinin  (200 KIU/ml) to inhibit 
urokinase and plasmin activity. Normal or anti-PAI-1 IgG (100/~g/ml) was added to the cultures and photographs  were taken 5 h later. 
(A) Normal IgG; (B and C) anti-PAI-1 IgG. Bar, 25 #m. 
Etzler, 1987). Therefore, in culture, the ceils are dependent 
on  the  serum  proteins  fibronectin  and/or  vitronectin  for 
adhesion (Hayman et al., 1982). Experiments were designed 
to test whether the anti-PAI-1 IgG disrupted adhesion of HT- 
1080  cells to either vitronectin or fibronectin.  Cells were 
plated in wells coated with either vitronectin or fibronectin. 
After a  5-h  incubation,  cells on both substrates  appeared 
equally adherent and well spread.  At this time, anti-PAid 
IgG was added to the wells. Cells plated in wells coated with 
vitronectin began to retract within 2 h. By 5 h the cells were 
completely rounded but still attached to the dish (Fig. 5 B). 
Cells plated on fibronectin were not affected by the antibody 
(Fig.  5  C).  Cells  plated  on  a  mixture of vitronectin and 
fibronectin rounded as rapidly as cells plated on vitronectin 
alone  (Fig.  5  D).  These data  suggest  that  HT-1080 cells 
maintain  adhesion  by  interacting  with  vitronectin-PAi-1 
complexes. 
HT-1080 Cells Deposit PAI-1 on Vitronectin but Not on 
Ftbronectin-coated Substrates 
To determine  whether  HT-1080  cells  deposit  endogenous 
PAI-1 preferentially on vitronectin-or fibronectin-containing 
adhesion sites, SAM from cells plated into wells coated with 
either vitronectin or fibronectin was analyzed by Western 
inununoblotting.  Fig.  6  indicates that SAM prepared from 
vitronectin-coated wells was rich in PAI-1 (lane 2). PAI-1 was 
also detected in SAM prepared from wells coated with both 
fibronectin and vitronectin (lane 3). However, PAI-1 was not 
detected  in  SAM  prepared  from fibronectin-coated  wells 
Ciambrone and McKeown-Longo  Adherence  to Vitronectin-PAl-1  Complexes  2187 Figure 5.  Effect of anti-PAid  on HT-1080 cells plated onto fibronectin-or vitronectin-coated  wells. Wells were coated with 5 #g/ml of 
vitronectin (A and B) or fibroneetin (C) either individually or in combination.  (D). Cells (5  x  10  ~) in MEM containing  1% BSA were 
plated into these wells and allowed to incubate for 5 h. The medium was then removed and new medium containing  100 #g/ml of normal 
or anti-PAI-1 IgG was added to the wells. Photographs were taken 5 h after addition of the antibodies. (A) Normal IgG; (B-D) anti-PAI-1 
IgG. Bar, 25 #m. 
(lane/).  These findings indicate that HT-1080 cells deposit 
PAId  into vitronectin but not fibronectin-containing adhe- 
sion sites. 
PAI-1 Deposited on Vitronectin by HT-1080 Cells 
Is Active 
To determine whether PAI-1 was inhibiting cell-associated 
urokinase, HT-1080 cell monolayers were tested for the abil- 
ity to activate exogenous plasminogen.  Cells were seeded 
into wells coated with purified human vitronectin or fibro- 
nectin and allowed to adhere for 7 h. In some wells, an mAb 
directed against the active site of PAL1  was used to block 
PAI-1 activity. Unlike the polyclonal antibodies (Fig. 5 B), 
monoclonal anti-PAI-1 did not disrupt cell adherence to vi- 
tronectin (Fig. 7 A). Monolayers containing active and inac- 
tive PAId  were then  compared for their  susceptibility to 
plasminogen-dependent retraction of cells from the substrate. 
12 h after the addition of either 5 or 15 #g of plasminogen, 
cell layers containing anti-PAid  antibody showed evidence 
of active plasmin (Fig.  7,  C  and D).  Cells have retracted 
from each other and from the substrate. Plasminogen had no 
effect on cell layers that did not receive anti-PAil antibody 
(Fig.  7 B). 
Similar  results  were  obtained  when  PAI-1  activity was 
modulated by the  substrate  rather than by the  mAb.  Cell 
layers plated on fibronectin-coated wells were disrupted after 
the addition of plasminogen to the medium (Fig. 7 F), while 
cells adherent to vitronectin were unaffected (Fig. 7 B). To 
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blot of substrate-attached ma- 
terial.  24-well tissue  culture 
plates were coated with 5 ~g/ 
ml of fibronectin or vitronec- 
tin  either individually  or  in 
combination. 5 ×  105 cells in 
MEM containing 1% BSA we~ 
then plated  into these  wells 
and allowed to adhere for 7 h. 
SAMs were made as described 
in Materials  and Mefl~ds. Sub- 
strate-attached  material  was 
solubilized  in reducing  gel sam- 
ple buffer and electrophoresed 
into  a  polyaerylamide  gel. 
Proteins  were  transferred  to 
nitrocellulose and  PAId  was 
detected  using mAb against hu- 
man PAL1. (lane 1 ) Fibronec- 
tin-coated wells. (lane 2) Vi- 
tronectin-coated  wells. (lane 
3) Fibronectin- and vitronec- 
tin-coated  wells.  Position  of 
molecular  weight markers  is 
shown on the right. 
verify that the changes in cell morphology were due to in- 
creased plasmin  activity,  the  cell-associated plasmin  was 
measured using  the  chromogenic substrate,  spectrozyme- 
PL. Fig.  8 A shows that after the addition of plasminogen, 
a twofold increase in plasmin activity could be detected on 
cells plated onto fibronectin, whereas plasmin levels were 
increased only onefold on cells plated onto vitronectin. After 
the inactivation of PAId, vitronectin adherent cells could ac- 
tivate plasminogen to the same extent as fibronectin adherent 
cells. Fig. 8 B shows that the activation of plasminogen by 
cells adherent to vitronectin can be modulated by neutraliz- 
ing antibodies against both PAl-1 and urokinase. These data 
suggest that PAl-1 bound to substratum vitronectin is active 
and can inhibit surface-bound urokinase on HT-1080 cells, 
preventing plasmin generation in the vicinity of the vitronec- 
tin molecule. 
l~bronectin Is Degraded at a Faster Rate than 
Vitronectin by HT-1080 Cells 
To test whether HT-1080 cells preferentially degrade substra- 
tum fibronectin, cells were plated into wells coated with ei- 
ther l~I-fibronectin or ~25I-vitronectin. Conditioned medium 
from the wells was then analyzed at various times for release 
and fragmentation of labeled proteins. Fig. 9 shows the cell- 
mediated release of radioactivity from the substrate. After 
an initial 15-rain lag period, radioactivity began to accumu- 
late  in  the medium.  Over a  9-h  time course,  the rate of 
fibronectin release from the substrate was threefold greater 
than the rate of vitronectin release. When analyzed by SDS 
gel electrophoresis and autoradiography, both conditioned 
media  showed evidence of protein degradation  (data  not 
shown). Thus, these cells degrade both adhesion molecules, 
but the degradation of fibronectin is much more rapid. 
Acquisition of  Sensitivity to Anti-PAl-1 by 
HT-1080 Cells 
To determine how soon after plating the cells become sensi- 
tive to the adhesion disrupting activity of  the polyclonal anti- 
PAId, anti-PAid IgG was added at various times after plating 
and the cells observed 3.5 h later. The addition of anti-PAL1 
IgG to the medium at the time of plating had no effect on ei- 
ther cell attachment or spreading when the cells were ob- 
served 3.5 h later (Fig. 10 B). However, if the cells were al- 
lowed to attach and spread for 1 h  before the addition of 
antibody, retraction of cells from the substrate could be seen 
within the 3.5-h time frame (Fig. 10 D). These results indi- 
cate that although the antibody had no effect  during the initial 
stages of cell adhesion, the cells soon became sensitive to 
the antibody. The 1-h delay before the cells acquire sensitiv- 
ity to the anti-PAL1 IgG no doubt reflects, in part, the time 
required  for sufficient PAL1  deposition.  In  addition,  the 
antibody-mediated disruption of adhesion may require the 
dissolution of fibronectin-dependent contact points. 
To determine whether the degradation of fibronectin con- 
taining contacts was a prerequisite to anti-PAL1 IgG-medi- 
ated detachment, serine protease inhibit0rs were added to 
the cultures at the time of plating. If the proteolytic removal 
of fibroneodn-dependent contacts facilitated the antibody- 
mediated  detachment,  the  addition  of protease inhibitors 
should extend the 1-h lag period during which the cells are 
insensitive to the anti-PAid IgG. Cells plated without inhibi- 
tors round up within 4  h in the presence of anti-PAI-1  IgG 
(Fig.  11 B). The antibody had no effect on the cells which 
were plated with inhibitors (Fig.  11 D). However, by 8 h, 
these cells were as rounded as control cultures treated with 
anti-PAL1  (data not shown). Although the protease inhibi- 
tors could extend the lag time during which the cells became 
responsive to the antibody, antibody-mediated detachment 
was not prevented. 
We propose that during initial plating in serum the cells 
attach and spread on both vitronectin and fibronectin, and 
that anti-PAI-1 IgG has no effect on this process. As the cells 
secrete and deposit PAL1 into vitronectin containing adhe- 
sions, local urokinase activity is inhibited and vitronectin is 
spared  from plasmin  degradation.  Fibronectin-dependent 
adhesions are preferentially degraded. Eventually, the cells 
become  primarily  dependent  on  vitronectin-PAI-1  com- 
plexes for adhesion. It is at this time that the cell adhesion 
can be disrupted with anti-PAI-1  IgG. 
Discussion 
Previous studies have indicated that the changes in cell mor- 
phology which accompany glucocorticoid treatment of HT- 
1080 cells (Oliver et al., 1983; McKeown-Longo and Etzler, 
1987) are correlated with an increase in PAL1 production 
(Andreasen et al., 1987; Pollanen et al., 1987). To probe the 
function of PAI-1 in HT-1080 cell layers, polyclonal antibod- 
ies against PAL1 were prepared. When added to confluent 
cultures of HT-1080 cells, antibodies caused rapid retraction 
and subsequent detachment of cells from the substrate. This 
effect was specific for anti-PAI-1 antibodies as IgG from nor- 
mal serum and antiurokinase antibodies did not cause retrac- 
tion. The disruption of cell adhesion by the anti-PAI-1  anti- 
bodies was not dependent on the activation of urokinase or 
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Figure 8.  (A ) Cell-associated 
plasmin activity. Parallel cul- 
tures to those shown in Fig. 7 
were rinsed three times and in- 
cubated with Spectrozyme PL 
in MEM containing 0.1% albu- 
min for 90 rain at 37°C. Plas- 
min activity  was determined 
by reading the OD at 410 nm. 
The open bars represent cells 
plated  onto vitronectin.  The 
hatched  bars  represent  ceils 
plated  onto  fibronectin.  (B) 
Total plasmin  activity.  Cells 
were  plated  as  described  in 
Fig.  7 except that one  set of 
wells was incubated with both 
an mAb against the active site 
of PAI-1 and an mAb against 
the active site of urokinase (10 
#g/ml).  After the  12-h incu- 
bation  with  exogenous  plas- 
minogen, Spectrozyme PL was 
added to the medium and the 
OD at 410 was measured after 
25 min. The data were plotted 
as the mean +  SEM of four 
determinations. 
plasminogen. Inactivation of urokinase, plasminogen deple- 
tion and serine protease inhibitors had no effect on the ability 
of antibodies to disrupt adhesion of confluent monolayers. 
The ability of the polyclonal antibodies to inhibit the active 
site of PAId  was not tested, but an mAb that does inhibit 
PAId's ability to block urokinase did not elicit cell detach- 
ment (Fig. 3), suggesting that the adhesion disrupting ability 
of the anti-PAid antibodies did not result from disinhibition 
of urokinase. However, the mAb could elicit cell detachment 
if a  second antibody, directed against the monoclonal anti- 
body, was added to the cell layer (data not shown). In fact, 
the adhesion disrupting activity of the monoclonal was en- 
hanced when experiments were performed on cells grown in 
plasminogen-depleted serum.  These data  suggest that the 
cell detachment resulted from a steric disruption of adhesion 
and not from the active degradation of adhesion proteins or 
receptors. 
In vitro, cell adherence is thought to be initiated by the in- 
teraction of RGD-dependent receptors for the serum proteins 
fibronectin and vitronectin (Ruoslahti,  1988). The addition 
of RGD-containing peptides also caused rapid rounding and 
detachment of HT-1080 cells (data not shown),  indicating 
that the cells were not adhering directly to PAId. Recently, 
purified PAId has been shown to bind to both soluble and 
immobilized vitronectin (Declerck et al., 1988; Mimuro and 
Loskutoff,  1989;  Salonen et al.,  1989).  Results presented 
here provide the first in situ evidence that cells specifically 
deposit PAId on vitronectin. The sensitivity of HT-1080 ad- 
hesion to Fab fragments prepared against PAId suggests that 
the binding site on vitronectin for PAId is close to, but does 
not overlap, the binding site for the vitronectin receptor. This 
is in agreement with previous studies  showing that PAId- 
vitronectin complexes support cell adhesion (Salonen et al., 
1989). Consistent with these observations, subcellular local- 
ization of newly synthesized PAId was dependent on vitro- 
nectin  (Fig.  6).  Cells  plated onto  fibronectin-coated sub- 
strates did not accumulate detectable quantities of PAId on 
the substrate. Whether the absence of PAI-1 from the fibro- 
nectin  substratum was due to a  redistribution  of secreted 
PAId or a decreased rate of PAId  synthesis is not known. 
It is possible that the synthesis of PAId may be regulated by 
interaction of the vitronectin receptor with vitroncctin. Anti- 
bodies against the fibronectin receptor have been shown to 
trigger an increase in the synthesis of collagenase and stro- 
melysin by cultured  fibroblasts (Werb et al.,  1989).  How- 
ever, preliminary data (Ciambrone and McKeown-Longo, un- 
published observations) indicate that vitronectin determines 
the localization and not the synthesis rate of PAId. 
The PAId bound to the vitronectin was active. Inactivation 
of cellular PAId  either by using an inhibitory monoclonal 
(Fig. 7, C and D) or by removing vitronectin from the sub- 
strate (Fig. 7 F), resulted in increased plasmin activity and 
in subsequent disruption of cell adhesion by a plasminogen- 
dependent mechanism. The increase in plasmin activity after 
Figure 7.  Effect of PAI-1 inactivation on plasminogen-dependent  cell detachment.  HT-1080 cells,  (5  x  105) in MEM containing  0.1% 
BSA, were plated into vitronectin (A-D) or fibroncctin (E and F)-coated wells and allowed to adhere for 7 h. All wells received mAb 
against tPA (25 #g/ml).  mAb (50 #g/ml) directed against the active site of PAI-1 was added to three wells (A, C, and D).  1 h later, 5 
#g/ml (B, C, and F) or 15 #g/ml (D) of human plasminogen was added to wells. After an additional  12 h of incubation, cells were pho- 
tographed  and plasmin assays (see Fig.  8) were done.  Bar, 25 #m. 
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Figure  9.  Release  of bound protein by HT-1080 cells.  Wells were 
coated with 'z~I-fibronectin or t25I-vitronectin at  10 #g/ml as de- 
scribed in Materials  and Methods.  Cells  (5  x  105) in MEM con- 
taining 1% BSA, were plated into these wells and allowed to incu- 
bate  for various periods of time.  Coated control wells  received 
neutralization  of PAId  was completely dependent  on uro- 
kinase.  We have done experiments both in the presence and 
absence of neutralizing antibodies against tPA, and found no 
tPA activity associated with the surface of these cells.  This 
is consistent with previous results showing that these cells do 
not secrete tPA (Stephens et al.,  1989). These data indicate 
that the active site of vitronectin bound PAl-1 is available to 
1 ml/well of MEM containing 1% BSA and were incubated for the 
same periods of time.  Radioactivity released  into the medium of 
wells without cells was subtracted  from the radioactivity  released 
into the medium of weUs with cells. The result was divided by total 
cpm of coated protein at zero time to yield the percentage of coated 
protein released.  Fibronectin-coated  (e-e). Vitronectin-coated  (n- 
[]).  Data shown is mean  +  SEM and is a representative  experi- 
ment with triplicate determinations  for each time point and protein. 
Degradation rates were calculated during the last 9 h of incubation 
using the  slopes  of each line.  Slopes were calculated  by linear 
regression  analysis. 
Figure 10.  Effect of anti-PAI-1 on initial attachment and spreading.  Ceils (5  x  105) in complete medium were plated  into 12-well tissue 
culture plates  and incubated in the presence of anti-PAI-1 IgG (B and D) or normal IgG (A and C). Antibodies,  50/~g/ml, were added 
either at the time of plating (A and B) or 1 h after plating  (Cand D). Photographs were taken 3.5 h after the addition  of antibodies.  Bar, 
25 pm. Figure 11. Effect of plating HT-1080  cells with serine protease inhibitors on the anti-PAid mediated detachment response. Ceils (5 x  105) 
in complete medium were plated into 12-well tissue culture plates in the presence (C and D) or absence (A and B) of the serine protease 
inhibitors p-nitrophenyl-guanidino-benzoate (40/,M) and diisopropylfluorophosphate (250 #M).  1 h after seeding, normal or anti-PAI-1 
IgG was added directly to the wells to a final concentration of 50 t~g/ml. The photomicrographs were taken 4 h after antibody addition. 
(A and C) Normal IgG. (B and D) Anti-PAM IgG. Bar, 25 ~m. 
inhibit cell-surface urokinase when the cells are adherent to 
vitronectin. This is consistent with a previous report show- 
ing that purified PAi-l-vitronectin complexes can inhibit uro- 
kinase  activation of plasminogen  (Salonen  et  al.,  1989), 
however, the present report represents the first demonstra- 
tion that substrate-associated PAl-1 regulates urokinase ac- 
tivity and that this regulation can be modulated by the nature 
of the substrate. 
Anti-PAid antibodies did not block initial attachment and 
spreading of newly plated cells, suggesting that the vitronec- 
tin in the FBS is not complexed with PAid to a significant 
extent. Time course studies indicated that there was a 1-h lag 
period before the cells became sensitive to the anti-PAI-1 an- 
tibodies. This lag probably reflects in part the time required 
for synthesis and secretion of PAI-1. The lag period could be 
extended several hours by the addition of serine protease in- 
hibitors. The presence of fibronectin in the serum and the 
fact  that  HT-1080 cells  are  known  to  secrete fibronectin 
(Oliver et al.,  1983),  suggests that the cells may establish 
some  initial  contacts  on  fibronectin.  Since  fibronectin- 
dependent contacts are not disrupted by anti-PAid antibody, 
the removal of substrate fibronectin would be expected to 
facilitate the antibody response. The removal of fibronectin- 
dependent contacts during initial spreading would explain 
why cells plated onto substrates coated with both fibronectin 
and vitronectin responded to the anti-PAl-1 IgG as rapidly as 
cells plated on vitronectin alone (Fig.  5). 
Endothelial cells also secrete PAl-1  into the subceUular 
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ever, we were unable to disrupt endothelial cell monolayers 
using  anti-PAI-1  antibodies  (data  not  shown).  Endothelial 
ceils produce an extensive subeellular matrix, which would 
be expected to provide alternate adhesion sites. As only cul- 
tured hepatoma cells have been shown to synthesize vitro- 
nectin (Barnes et al., 1985), the previously described bind- 
ing  site for PAI-1 in the endothelial matrix (Mimuro and 
Loskutoff,  1989)  is probably  serum vitronectin.  In vitro, 
binding sites in the matrix for serum vitronectin could in- 
clude heparan  sulfate proteoglycans  (Suzuki et al.,  1984) 
and collagen (Gebb et al.,  1986).  In vivo,  vitronectin has 
been detected in the matrix of a number of tissues by immu- 
nocytochemical techniques (Hayman et al., 1983; Simonton 
et al.,  1985).  However, p/asma vitronectin interacts  poorly 
with heparin (Barnes et al., 1985; Hayoshi et al., 1985) and 
collagen (Gebb et al.,  1986).  Therefore, the mechanism of 
vitronectin incorporation into tissue matrix remains to be 
clarified. 
Previously, urokinase has been localized to focal contact 
areas  in HT-1080  and  human  fibroblasts  (Pollanen et al., 
1988;  Hebert and Baker,  1988).  These experiments could 
not distinguish inactive proenzyme from active enzyme. In 
other studies, antibodies against urokinase have been shown 
to inhibit HT-1080 cell-mediated destruction of extracellular 
matrix indicating the presence or some active enzyme (Berg- 
man et al., 1986; Reich et al., 1988). The experiments pre- 
sented here represent the first demonstration that PAL1 is 
directly regulating  urokinase activity in cell adhesion sites. 
Distribution of urokinase to sites of cell-substrate adhesion 
would help confine proteolytic activity to discrete areas. Lo- 
cal proteolysis, by releasing a limited number of adhesion 
sites, could facilitate directed cell migration and tumor inva- 
sion.  Local deposition of PALl  would permit reestablish- 
ment of contacts by decreasing urokinase activity.  The abil- 
ity of vitronectin to modulate plasmin activity suggests a role 
for matrix components in regulating  the invasive properties 
of a tumor. 
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